Company Profiles

driven by the PitchBook Platform

Exicure

Description

Developer of immunomodulatory and gene silencing drugs against validated targets. The company's spherical nucleic acid (SNA™) architecture accesses the potential of nucleic acid therapeutics in multiple organs. The company's lead programs address diseases from inflammatory disorders to oncology. SNA constructs enable safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents, and can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

2009

Founded

PRIVATE

Status

11-50

Employees

Series C

Latest Deal Type

$15M

Latest Deal Amount

$44.6M

Total Amount Raised

Description

Developer of immunomodulatory and gene silencing drugs against validated targets. The company's spherical nucleic acid (SNA™) architecture accesses the potential of nucleic acid therapeutics in multiple organs. The company's lead programs address diseases from inflammatory disorders to oncology. SNA constructs enable safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents, and can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Website:

www.exicuretx.com

Formerly Known As

AuraSense Therapeutics

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Delivery

Primary Office

8045 Lamon Avenue Suite 410 Skokie, IL 60077United States +1 (847) 673-1700
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Exicure's full profile, request a free trial.

Exicure Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Exicure Investors (11)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AbbVie Biotech VenturesCorporate Venture CapitalMinority000 0000000 0000
Craig MundieAngel (individual)Minority000 0000000 0000
David WaltAngel (individual)Minority000 0000000 0000
Gates VenturesOtherMinority000 0000000 0000
Hercules CapitalGrowth/ExpansionMinority000 0000000 0000
AbbVie Biotech Ventures Corporate Venture Capital
Craig Mundie Angel (individual)
David Walt Angel (individual)
Gates Ventures Other
Hercules Capital Growth/Expansion

Exicure Executive Team (5)

NameTitleBoard
Seat
Contact
Info
David Giljohann Ph.DChief Executive Officer & Board Member
David SnyderChief Financial Officer
Ekambar Kandimalla Ph.DChief Scientific Officer
Gordon Beck Ph.DVice President, Business Development
James TyreeAdvisor
David Giljohann Ph.D Chief Executive Officer & Board Member
David Snyder Chief Financial Officer
Ekambar Kandimalla Ph.D Chief Scientific Officer
Gordon Beck Ph.D Vice President, Business Development
James Tyree Advisor

Exicure Board Members (8)

NameRepresentingRoleSinceContact
Info
C. Shad Thaxton Ph.DSelfCo-Founder & Board Member000 0000
Chad Mirkin Ph.DSelfCo-Founder & Board Member000 0000
David Giljohann Ph.DExicureChief Executive Officer & Board Member000 0000
David Walt Ph.DSelfBoard Member000 0000
Helen KimSelfBoard Member000 0000
C. Shad Thaxton Ph.D Co-Founder & Board Member Self
Chad Mirkin Ph.D Co-Founder & Board Member Self
David Giljohann Ph.D Chief Executive Officer & Board Member Exicure
David Walt Ph.D Board Member Self
Helen Kim Board Member Self
Request full access to PitchBook